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Abstract: Exercise-induced asthma/exercise-induced bronchospasm (EIA/EIB) is a prevalent 
and clinically important disease affecting young children through older adulthood. These 
terms are often used interchangeably and the differences are not clearly defined in the 
literature. The pathogenesis of EIA/EIB may be different in those with persistent asthma 
compared to those with exercise-induced symptoms only. The natural history of EIA is unclear 
and may be different for elite athletes. Leukotriene biology has helped the understanding of 
EIB. The type and intensity of exercise are important factors for EIB. Exercise participation 
is necessary for proper development and control of EIA is recommended. Symptoms 
of EIB should be confirmed by proper testing. Biologic markers may also be helpful in 
diagnosis. Not all exercise symptoms are from EIB. Many medication and nonpharmacologic 
treatments are available. Asthma education is an important component of managing EIA. 
Many medications have been tested and the comparisons are complicated. Montelukast is a 
US Food and Drug Administration-approved asthma and EIB controller and has a number 
of potential advantages to other asthma medications including short onset of action, ease of 
use, and lack of tolerance. Not all patients improve with montelukast and rescue medication 
should be available.
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Introduction to EIA and management  
strategy overview
eiA vs eiB
The use of the term “exercise-induced asthma” (EIA) began during the 1960’s.1 
Subsequently the terms “EIA” and “exercise-induced bronchospasm” (EIB) 
are often used interchangeably.2 However, EIB specifically denotes the reduc-
tion in lung function after a standardized exercise test.1,3,4 “Exercise-induced 
bronchoconstriction” is another term that has been used in the literature.5 Some 
clinicians/authors use EIA to describe individuals with known asthma who have 
bronchoconstriction during exercise.6–8 However, some use EIA to describe patients 
that have bronchoconstriction only during exercise, and use EIB to describe patients 
with asthma that have bronchoconstriction with exercise.9 Therefore, the use of the 
terms “EIA” and “EIB” in the literature is unclear.1 For this review I will use the 
term EIB primarily to indicate bronchospasm with decreased pulmonary function 
testing following exercise and EIA to indicate those patients with asthma difficulties 
associated with exercise.Journal of Asthma and Allergy 2009:2 94
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Overview
Asthma and allergic rhinitis are closely associated with EIB 
and are the most common chronic diseases affecting US 
children.10 The prevalence of asthma is increasing11 as is EIA.4 
Exercise is a common trigger for asthmatics, and for some, it is 
the only trigger.12,13 EIA affects patients in all levels of asthma 
severity, but perhaps with higher prevalence in children with 
asthma14 and many are recognized as having asthma features 
at rest.15 Asthma is heterogeneous16 and EIB is likely also 
heterogeneous. The predominant symptoms of EIA are cough, 
wheeze, shortness of breath, and chest discomfort associated 
with exercise.12 The physical examination may be normal or 
consistent with asthma.12 The likelihood of different forms 
of exercise causing asthma symptoms is often referred to its 
“asthmagenicity.”12 For instance, for most asthmatics running 
is more likely to cause EIA than swimming. More intense 
exercise is also more likely to lead to asthma symptoms espe-
cially if not preceded by a warm-up exercise (see subsequent 
section on nonpharmacologic treatment of EIB).
EIB may be the result of an overall lack of asthma 
control13,17 and a professional athlete with EIA has a form of 
occupational asthma18 impairing performance.19 Exercise is 
the most common trigger of bronchospasm in children with 
asthma3,12 and worsens quality of life and limits activity.15,20–22 
Interestingly, the lungs and airways do not respond to exercise 
training by increasing their capacity similar to the peripheral 
muscles and the cardiovascular system.4 After experiencing 
a significant EIA event, future exercise-related activities 
may be limited19 and parents of children with asthma have 
been shown to intentionally or inadvertently restrict their 
child’s activity.22 In children with mild-to-moderate asthma, 
exercise limitation is a primary complaint17 and EIA may 
interfere with activities important for physical and social 
development.22–25 Vilozni and colleagues documented EIA 
in children as young as three years old.21
Regular physical activity is important to health and 
well-being. Full participation in sporting activities is one of 
the important goals of asthma management.3,13,22,26 Moderate 
exercise has been shown to stimulate the immune system.27 
Physical activity is a significant component of daily life in 
childhood and adolescence, so for those affected with EIA it 
can be an equally significant problem.3 Children and young 
adults with asthma are more affected by EIB than adults with 
asthma and therefore EIA is more common for them perhaps 
because of their increased levels of physical activity.25,28,29 
Poor perception of EIA symptoms is common and the child 
may fail to notice the symptoms and others may not take note 
of the limited performance.21,22
The natural history of EIA is unknown. Does asthma 
resolve if a patient with EIA stops exercising? Does lung 
function decline more rapidly in a patient with EIA who 
continues to exercise?18 These questions remain unanswered. 
While this is only a brief overview, more comprehensive EIA 
reviews and guidelines are available.12,30
eiA pathogenesis
In EIB, the airway epithelium is likely disrupted and along 
with inflammatory cells may be the basis of  EIB31 (Table 1). 
EIB may represent a distinct phenotype31 and EIB pathogenesis 
in a chronic asthmatic may be from a different mechanism 
than a person who only has asthma symptoms with exercise.32 
Exercise provides multiple stimuli to induce bronchospasm 
and hyperpnea is thought to be dominant.33 Endurance 
events appear to be higher risk for developing EIB19,34 and 
the literature remains unclear regarding whether a late-phase 
response occurs in EIB.35
Hyperpnea induces bronchoconstriction through water 
loss in the “osmotic hypothesis” or airway cooling in 
the “heat-loss hypothesis.”3,4,12 Because asthma is more 
common in swimmers compared to other sports, some have 
suggested a pool chlorine hypothesis as an explanation.36–38 
However, asthmatics may tolerate swimming better than 
other activities36 and swimming is considered a beneficial 
whole body exercise.37 Ice rink-related athletes are thought 
to be at higher risk of EIB from airborne ultrafine particulate 
matter released by ice-resurfacing machines.4
Exposure to cold air, allergens, chlorinated pools, or high 
levels of pollutants may sensitize or irritate the airways.34 
Risk factors for EIB include family history of atopy, positive 
skin prick testing, allergic rhinitis and eczema39 as well as 
others and have been reviewed in other works.12 Atopy is a 
major risk factor for EIB in some and controlling rhinitis 
may improve asthma control.19 Exposure to indoor allergens 
is a risk factor for EIA and immunotherapy is a protective 
factor.33 Some studies have shown elite athletes to be at 
higher risk of atopy,8 but some studies have shown that 
elite athletes are not at higher risk of allergic sensitization.26 
Children with human immunodeficiency virus and treated 
with highly active antiretroviral therapy (HAART) have an 
increased risk of asthma.40
Table 1 Pathogenesis hypotheses
Osmotic-water loss
Thermal-heat loss
Pool chlorine
Airway sensitization-chemical mediatorsJournal of Asthma and Allergy 2009:2 95
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Chemical mediators of an inflammatory cascade including 
histamine, prostanoids, and leukotrienes are thought to be 
central in the pathogenesis of EIA.3 Of note specifically to 
this review, the levels of cysteinyl leukotrienes are elevated 
after exercise in asthmatics with EIB.31 Also, eosinophils 
with a hyperosmolar stimulus generate and release cysteinyl 
leukotrienes.41 Eosinophil levels in blood and sputum have 
been correlated to the presence and severity of EIB.41 The 
serum concentration of eosinophil cationic protein (ECP), 
a cytotoxic protein causing desquamation and bronchial 
epithelial destruction with bronchial hyperactivity, is also 
higher in asthmatic children with EIB after exercise.42 Overall, 
further research in the causation of EIA is needed.7
Confirmation testing
Exercise tests are commonly utilized to confirm clinical 
concerns of asthma in children39 and history of symptoms 
alone is not adequate to diagnose EIB.13,32 The American 
Thoracic Society and the European Respiratory Society 
published guidelines for pulmonary function testing 
including specific statements for preschool children.43 
Exercise testing has been specifically addressed as well.44 
Patients with near-normal airway function at rest may still 
have significant EIA that limits their ability to exercise.15 
Airway hyperresponsiveness to exercise suggests a lack of 
asthma control45 and female athletes have greater airway 
hyperresponsiveness than male athletes.46
EIB challenges are subdivided as direct or indirect 
with direct challenges acting on airway smooth muscle 
receptors and indirect challenges reflecting the degree of 
airway inflammation.6 Methacholine challenge is the most 
commonly used direct test.34 Indirect tests include exercise, 
eucapnic voluntary hyperpnea (EVH; also known as 
isocapnic hyperventilation test), and hyperosmolar aerosols 
such as hypertonic saline and mannitol acting through the 
release of mediators.34
An exercise challenge is done to reproduce a patient’s 
symptoms and signs and to document pulmonary function 
changes to confirm or refute the diagnosis of EIA.12 
A 10%–20% reduction in forced expiratory volume in one 
second (FEV1) or peak expiratory flow (PEF) following 
exercise and an improvement with a bronchodilator is 
consistent with EIB.12 Exercise challenges are expensive, 
require significant space, are complex and time intensive, 
as well as uncomfortable for patients.29,47 A free running test 
is the most familiar, most asthmagenic, and least expensive 
exercise challenge47,48 and therefore most convenient.21 
Inhaling cold, dry air has been shown to be EIB’s most 
potent trigger.3 Impulse oscillometry can be used to detect 
EIB in young children39 and EVH may overdiagnose EIB.47 
The coding and billing for physician services related to EIB 
testing is reviewed by Pohlig.47
Surrogate tests and biologic markers
Biologic markers measured from the lungs may reflect 
more accurately EIB related changes compared to other 
biologic fluids such as urine and blood from less systemic 
dilution.28 The main mediator of neural (nonadrenergic 
noncholinergic) bronchodilation is thought to be nitric oxide 
(NO).14 In 20 asthmatic children, Nishio and colleagues 
found that exhaled NO (eNO) was significantly higher in the 
EIB-positive group than in the EIB-negative group evaluating 
fall in FEV1 and forced expiratory flow (FEF)25%–75% following 
bicycle ergometer exercise testing.49 Lex and colleagues 
studied 85 children with atopic asthma aged 5–16 years 
and found EIB was not seen with eNO  25 ppb and that 
symptom questionnaires were almost as reliable as eNO at 
ruling out EIB.29 Carraro and colleagues evaluated 19 children 
aged 7–18 years with asthma compared to 14 healthy 
controls using a treadmill exercise test.28 Those with EIB 
were treated with montelukast for three days and testing 
was repeated. Measurements of exhaled breath condensate 
levels of cysteinyl leukotrienes, leukotriene B4, ammonia 
concentrations, and fraction of eNO were obtained. EIB 
patients had higher levels of cysteinyl leukotrienes at baseline 
compared to non-EIB patients and controls. After three days 
of montelukast, cysteinyl leukotriene levels decreased by a 
statistically nonsignificant amount and no significant change 
was noted in fractional eNO either. However, maximal fall 
in FEV1 did show improvement. In the overall group of 
children with asthma, the maximal post-exercise fall in FEV1 
correlated with the cysteinyl leukotriene level. 8-isoprostane, 
an oxidative stress marker derived from the free radical-
catalyzed peroxidation of arachidonic acid on plasma 
membrane phospholipids was measured in the exhaled breath 
condensate of 46 children and adolescents and baseline levels 
were higher in the EIB group.14 A direct role for chemokines 
in EIB was not observed in childhood asthma.50
Treatment
Overall asthma management in athletes is similar to 
nonathletes with asthma.34 EIB can be the initial symptom 
trigger of asthma and the last to resolve with medication.1 
Exercise tolerance is one of the important measures of 
asthma control and therefore should be monitored by 
exercise testing.19,33 Asthma medication costs are a large Journal of Asthma and Allergy 2009:2 96
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part of asthma expenditures.51 Many medications have been 
used in the treatment of EIA and have included albuterol, 
salmeterol, formoterol, montelukast, ipratropium bromide, 
calcium channel blockers, inhaled furosemide, theophylline, 
cromolyn, nedocromil, and inhaled corticosteroids.8,19,23–25,48 
Choice between these agents is based on onset, efficiency, 
safety profile, ease of use, compliance, cost, and duration 
of action.12,13,16,52
Asthma education to develop and improve self management 
skills should be included in overall asthma management.22,30 
Unfortunately, school policies may not facilitate asthma 
management and may lead to opting out of exercise.22 
Parents, children, teachers, coaches, and trainers require 
asthma education regarding exercise participation, asthma 
medication adjustment, and how to distinguish between 
normal physiologic and asthma exercise limitations.22
Therapeutic use exemptions
Some have been concerned that athletes without asthma have 
also been using β2-agonists.34 Doping is defined as the use 
of forbidden substances and methods intending to improve 
an athlete’s performance. The World Anti-Doping Agency 
has a prohibited list of medications as well as therapeutic 
use exemptions for medications including β2-agonists and 
glucocorticosteroids.53 From 2003–2008, 868 therapeutic 
use exemptions for β2-agonists were received by the 
International Association of Athletics Federations and 80% 
were approved.34 No ergogenic effects of inhaled β2-agonists 
or inhaled steroids have been demonstrated.8 β2-agonists and 
inhaled corticosteroids are not thought to improve an athlete’s 
performance outside of improving asthma control.4 The use 
of inhaled β2-agonists by athletes has increased and perhaps 
were previously underused.34 The International Olympic 
Committee has recommended a diagnosis based on symptoms 
be confirmed with pulmonary function testing.34
Nonpharmacologic treatment of eiB
Reducing asthma trigger exposures and warm-up pre-exercise 
is important in preventing EIB.1,11,30 Breathing through the 
nose during exercise1 and a face mask when exercising in cold 
air may be helpful.8,19,34 A cool-down exercise may also be 
helpful in reducing EIB episodes.1,19 Aerobic exercise training 
reduced bronchial hyperresponsiveness and the improvements 
were enhanced with concomitant montelukast.54 Patients with 
EIA should be cautioned not to exercise when their asthma 
is not under control.12
Avoiding training in suboptimal environments should 
reduce airway penetration of harmful factors during the high 
ventilation demands of intense exercise.34 Also reducing 
chlorine derivatives in swimming pools, ozone, and particulate 
matter may also be helpful in preventing EIB.34 Allergen 
avoidance in sensitized individuals is recommended.8 Diet 
may also influence EIB32 and increasing components such as 
omega-3 polyunsaturated fatty acids and antioxidant intake 
as well as reducing sodium may be helpful.8 Increasing 
vitamin C intake may decrease EIB as well.32
Precautions
The differential diagnosis of EIB has been reviewed in 
multiple studies.4,8,12 Not all dyspnea associated with exercise 
is from EIB12 and not all dyspnea when exercising in cold 
air is asthma either.55 For instance exercising in a cold 
environment reduces exercise capacity independent of EIB 
although the cold environmental conditions aggravated the 
effects of EIB.56
Leukotriene biology
Exercise physical stress induced transcriptional changes, 
specifically in the leukotriene pathway have been shown 
to be enhanced following exercise and may play a role in 
EIB.2 Concentrations of cysteinyl leukotrienes are higher in 
asthmatic children with EIB3 and are thought to mediate the 
immediate reduction in airway caliber.20 Leukotrienes are a 
family of polyunsaturated eicosatetraenoic acids formed from 
the phospholipid layer.11 The two classes of leukotrienes are 
cysteinyl (LTC4, LTD4, LTE4) and noncysteinyl (LTB4).11 The 
cysteinyl leukotrienes all contain a thioether-linked peptide: 
glutathione in LTC4, cysteinyl-glycine in LTD4, and cysteine 
in LTE4.51
Cysteinyl leukotrienes are derivatives of the 5-lipoxygenase 
pathway of arachidonic acid metabolism and are one of the 
important mediators of airway inflammation including a 
role in the pathogenesis of EIA.3 Phospholipase A2 catalyzes 
the release of arachidonic acid from membrane phospholipids 
and the subsequent enzyme actions are reviewed by Riccioni 
and colleagues.2,51 The cysteinyl leukotriene synthesis 
pathway requires a series of sequential enzyme actions 
from 5-lipoxygenase, 5-lipoxygenase-activating protein, 
and leukotriene C4 synthase.57 Chromosome 5q35 encodes 
for the key enzyme leukotriene C4 synthase which converts 
leukotriene A4 to C4.57 Cysteinyl leukotrienes are released 
from activated inflammatory cells including mast cells 
and eosinophils,3,41 basophils,58 neutrophils, macrophages, 
epithelial cells, and vascular endothelial cells.11
Cysteinyl leukotrienes act on type I (Cys-LT1) receptors 
as a pro-inflammatory mediator with numerous local and Journal of Asthma and Allergy 2009:2 97
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systemic effects including bronchoconstriction and increased 
airway hyperresponsiveness, decreased activity of respiratory 
cilia, increased mucus secretion, increased venopermeability 
with plasma exudation, vasoconstriction, promotion of 
eosinophil migration into the airway mucosa, and airway 
smooth muscle proliferation.3,23,57–60 The Cys-LT1 receptor 
gene maps to the X chromosome.57 Leukotrienes are 100 
to 1,000 times more effective than histamine in inducing 
bronchospasm,3,59 and were previously known as the slow-
reacting substance of anaphylaxis.23 Ten to 20% of cysteinyl 
leukotrienes produced are released into the urine.3 In asthmatic 
patients, the urinary excretion of leukotriene E4 increases after 
exercise.61 Even high doses of oral steroids do not change 
urinary or airway secretion concentrations of leukotrienes.11
Pharmacology, mode of action,  
and pharmacokinetics of montelukast
Clinical pharmacology/biochemistry  
of montelukast
Montelukast is rapidly absorbed following oral administration 
with peak plasma concentrations in 2.6–4 hours and a mean 
bioavailability of 58%–73%,3,59 which is generally noted to 
be higher in chewable tablets.59 No dose-response relationship 
was observed down to a 10 mg once daily dose in adults and 
the children’s dose was chosen to provide a similar overall drug 
exposure anticipating similar efficaciousness.59 Absorption 
and pharmacokinetics is not much affected by meals or by 
the time of day administered, respectively.59,60 Steady state 
was reached on day 2 of administration.59 The mechanism 
of action is through high affinity and selectively binding to 
the Cys-LT1 receptor without agonist activity.62 Gender and 
advanced age do not significantly influence montelukast 
pharmacokinetics.59,62 Montelukast is extensively bound 
to plasma proteins with a volume of distribution average 
of 8–11 liters, minimal distribution across the blood–brain 
barrier, and minimal tissue concentrations 24 hours after 
administration.59,62 Montelukast is extensively metabolized 
in humans and is similar in pediatric and adult subjects.59 
Metabolites are excreted in bile with minimal amounts in 
plasma and 0.2% recoverable in urine.59
Once daily dosing at bedtime was chosen based on 
higher plasma levels at night when the circadian variation 
for asthma-related airway obstruction tends to be worse59 and 
when there may be a higher concentration of alveolar-tissue 
CD4+ lymphocytes.63 Pajaron-Fernandez and colleagues 
found no statistical difference in exercise challenge results 
when comparing morning vs evening montelukast dosing 
in 24 children aged 6–14 years, but showed better outcomes 
in some children with evening dosing.63 Medication-induced 
tolerance to the bronchoprotective effect over time has not 
been noted.3
Singulair overview
Singulair (Merck & Co., Inc., Whitehouse Station, NJ, USA) 
is an orally active, selective leukotriene receptor antagonist 
medication for treating asthma and allergic rhinitis.3,62 
Montelukast may also inhibit 5-lipoxygenase.2 Both single 
and multidose studies in adults and children have shown 
protection against EIA.3 Singulair is available in multiple 
oral formulations including a 10 mg film-coated tablet, 
4 mg and 5 mg chewable tablets, and 4 mg oral granules.3 
Singulair is administered 10 mg once daily to adults, 5 mg 
once daily to children aged 6–14 years, and 4 mg once 
daily to children aged 2–5 years for asthma treatment.59,62 In 
April 2007, the US Food and Drug Administration (FDA) 
approved montelukast as a single-dose preventative for EIB 
in patients aged 15 years or older.17 The response to asthma 
medications is variable,16 including montelukast.32 Predicting 
by genotype which patients will be poor or better responders 
to montelukast has been studied,57,64,65 but no clear clinical 
recommendations have been made.
Efficacy studies in children, 
adolescents, and adults
Complications in reviewing studies
Comparisons of the outcomes of studies evaluating the 
effectiveness of montelukast is complicated by many factors 
including the inclusion criteria of the studied group, particularly 
how the authors defined EIA and/or EIB. Other specific 
variations include age of the patients, subtype of asthma 
(eg, EIA only, intermittent, severity class of persistence), 
concomitant medications allowed (eg, inhaled corticosteroids, 
long- and short-acting β2-agonists, antihistamine), control 
at the time of the exercise challenge(s), aspirin sensitivity, 
severity of the allergic component, overall diet (eg, caffeine 
intake, omega-3, vitamin C), seasonal changes over the study 
period, as well as others were found in reviewing the studies. 
The end points and the comparisons made were also variable. 
Protocols of timing (eg, relative to medication dosage, time 
of day) and type of exercise challenge (treadmill, bicycle, 
free running) and duration of dosing were also variables 
making comparisons difficult. Small numbers involved in 
many studies led to limitations.
Various measurements have evaluated the effectiveness of 
EIB prevention. These measurements have included: reduction Journal of Asthma and Allergy 2009:2 98
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in the area under the FEV1 curve, the maximal decrease in 
post-exercise FEV1, time from the maximal decrease in FEV1 
to return to within 5% or 10% of pre-exercise values, number 
of patients who required β2-agonist rescue, asthma symptom 
score, and percentage of those protected. No end point is 
considered clearly the best. Many studies that used more than 
one end point sometimes found statistical significance with 
one or some, but not all end points. Some have suggested that 
an improvement in percentage decrease in FEV1 of 50% or 
greater relative to placebo-related decrease can be defined as 
clinically significant.61 In the following themed comparisons, 
I have arranged most of the studies chronologically.
Montelukast compared to placebo
Bronsky and colleagues studied 27 patients by exercise 
challenge 20–24 hours and 32–36 hours after montelukast 
0.4 mg up to 50 mg vs placebo.58 They found montelukast 
10 and 50 mg protected against EIB compared to placebo 
at 20–24 hours post-dose and only slight nondose-related 
effects were observed at 32–36 hours post-dose. Kemp and 
colleagues compared montelukast to placebo in 27 children 
aged 6–14 years and found improvements in EIB in the 
montelukast group.23 In a 12-week study, Leff and colleagues 
compared montelukast to placebo in 110 patients aged 
15–45 years by treadmill exercise challenge and found EIB 
protection with montelukast.45 No protective or rebound 
effects were found two weeks after treatment was stopped. 
Melo and colleagues studied 22 patients with a mean 
age of 12.6 years on a stationary bicycle and found less 
deterioration in lung function with montelukast compared 
to placebo including a late phase response in the minority of 
patients with a dual response.35 Kim and colleagues enrolled 
64 children aged 8–14 years to compare eight weeks of 
montelukast to placebo in an outdoor free running challenge 
and found the asthma symptom score significantly improved 
for the montelukast group.48 This improvement persisted 
after an additional eight weeks of placebo. de Benedictis 
and others studied 32 children aged 6–12 years for four weeks 
to compare montelukast to placebo by exercise challenge at 
days 3, 7, and 28 and found improvement with montelukast 
independent of concomitant inhaled steroids and without 
evidence of tolerance.66
In their study of almost 50 patients, Pearlman and 
colleagues showed improvement in protection from EIB 
by exercise challenge at two, 12, and 24 hours after dosing 
with a single dose of montelukast compared to placebo.61 
However, in their study of 19 patients aged 7–13 years Peroni 
and colleagues found protection with montelukast vs placebo 
with exercise challenge at 12 hours, but not at two or 24 hours 
following single-dose therapy.24 These authors point out that 
the dose of montelukast was received in the morning, that 
all study patients were on inhaled corticosteroids, and that a 
placebo effect has been documented. In a Merck-supported 
study by Philip and colleagues, montelukast was compared to 
a placebo in a group of patients aged 15–45 years two hours 
after a single dose using a treadmill exercise challenge and 
found significantly more patients receiving montelukast 
were protected from EIB.67 This protection was also noted 
at 12 and 24 hours postdose.
Montelukast compared  
to long-acting β2-agonists
In a Merck grant-supported study by Villaran and colleagues, 
197 patients aged 14–45 years were evaluated to compare 
montelukast and salmeterol over an eight-week time frame 
and improvements in both treatment groups was found, 
but montelukast had the greater effect.68 Patients treated 
with concomitant inhaled corticosteroids showed the same 
effect as those not on inhaled corticosteroids and tolerance 
to bronchoprotection was not prevented by concomitant 
inhaled corticosteroids. In a Merck-funded trial, Edelman 
and others studied 177 patients aged 15–45 years to compare 
eight weeks of montelukast to salmeterol.15 Within three days 
both groups showed EIB improvements. However, a loss of 
bronchoprotective effect was noted in the salmeterol groups 
at four and eight weeks whereas the montelukast effect was 
maintained. Storms and colleagues compared montelukast, 
salmeterol, and placebo over a four-week treatment period 
in patients aged 15–45 years.69 They observed a number of 
findings, including maximal post-albuterol rescue FEV1 
percent-predicted values improved in montelukast and 
placebo groups, but not in salmeterol with the maximum 
FEV1 lowest in the salmeterol group. Patients treated with 
montelukast had significantly greater alleviation of EIB com-
pared to placebo but the salmeterol group did not. The authors 
pointed out that concerns in the salmeterol group regarding 
long-acting β2-agonists decreased the effects of short-acting 
β2-agonists and tachyphylaxis with downregulation of 
airway smooth muscle receptor numbers. Uncoupling of 
intracellular signaling may occur even with concomitantly 
administered inhaled corticosteroids. Steinshamm and 
colleagues compared montelukast to salmeterol in 18 adults 
with EIB and concluded that montelukast has a favorable 
effect on gas exchange at moderate exercise compared to 
salmeterol.70 They also pointed out the suggestion that regular 
use of salmeterol leads to a decrease in rescue response Journal of Asthma and Allergy 2009:2 99
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to short-acting β2-agonists after exercise. Salmeterol and 
formoterol provide EIB protection after a single dose for 
up to 12 hours but their protective duration lessens when 
given regularly.61 In a Merck protocol, Philip and colleagues 
compared single-dose montelukast or salmeterol in 
47 patients aged 14–45 years by treadmill exercise challenge 
and found significant EIB protection within two hours of 
dosing and duration of at least 24 hours for montelukast.52 
The efficacy was similar in a magnitude to 50 µg of inhaled 
salmeterol with a longer duration. Stelmach and colleagues 
studied 91 patients aged 6–18 years with EIB and allergies 
comparing budesonide/formoterol, budesonide/montelukast, 
montelukast, budesonide, or matching placebo for eight 
weeks. They found the protective effect against treadmill 
exercise challenge better with montelukast and budesonide/
montelukast by comparison.9 They recommended that 
montelukast should be added to control EIB in children even 
if on low-dose inhaled steroid therapy.
The International Olympic Committee and others 
recommend against using LABAs as monotherapy.11,30,34 In 
an editorial by Dr Miles Weinberger, he states “clinicians 
would be wise to add LABAs selectively…so as to identify 
the occasional patient in whom the induced tolerance results 
in decreased clinical response to the β2-agonist inhaler that 
the patient uses for rescue and before exercise.”71 Szefler has 
made similar recommendations.40
Montelukast compared  
to short-acting β2-agonists
Raissy and colleagues studied 11 patients 7–17 years 
old with mild asthma with a treadmill exercise challenge 
comparing 3–7 days of montelukast or placebo with 
albuterol MDI pre-exercise and found the albuterol supe-
rior in preventing EIB.17 Hancox and colleagues evaluated 
a group of patients aged18–50 years with EIB by treat-
ing them with salbutamol or matching placebo for one 
week and found those treated with scheduled salbutamol 
had worsened EIB after dry-air cycle ergometer exercise 
challenge.72 In addition, the FEV1 remained significantly 
lower throughout the post-exercise salbutamol dose-
response rescue in those treated with scheduled salbutamol. 
The authors were concerned that patients with EIA treated 
with regular or frequent β-agonist medications will have 
worsening exercise symptoms and a reduced response 
to β-agonist rescue. The frequency, dose, and duration 
to develop these effects are unknown. A combination of 
receptor downregulation and proinflammatory mechanisms 
were postulated as causes.
The International Olympic Committee has stated that 
although “β2-agonists are likely to remain the most effective 
bronchodilators available in the foreseeable future” they 
“should be reserved for occasional use and breakthrough 
symptoms.”30 Tolerance to β2-agonists, usually only 
partial, is a concern, increasing the airway sensitivity to 
bronchoconstriction to exercise and allergen stimuli.34 The 
International Olympic Committee and others recommend 
against regular/frequent short-acting β2-agonist use as sole 
therapy for athletes with asthma.34
Montelukast compared to mast  
cell stabilizers
A study by Lecheler and colleagues compared a fixed 
combination of disodium cromoglycate plus reproterol 
(DSCG/REP) to montelukast in a group of children aged 
11–18 years and found that DSCG/REP before exercise 
was superior in preventing EIA.73 Significant limitations in 
this study are noted including small numbers and an open 
design among others.
Montelukast compared  
to inhaled corticosteroids
Vidal and others compared montelukast to budesonide in 
20 patients with EIA and found that budesonide provided 
improved protection to exercise challenge on a treadmill 
compared to montelukast in 16 patients (80%), but better 
protection with montelukast in the remaining four patients 
(20%).20 They concluded with the recommendation that 
both medications be tested in each patient prior to the final 
decision. Formoterol combined with budesonide was similar 
to budesonide alone suggesting little additional effect after 
eight weeks of treatment.9
Montelukast compared with loratadine
Peroni and colleagues compared placebo, loratadine, 
montelukast, and combination montelukast and loratadine in 
a single-dose test in 19 allergic-asthma children and found no 
statistically significant additive effect using the combination 
compared to montelukast alone.74 H1-antihistamines have 
been found to have minimal EIB effects.19
Montelukast compared  
to other leukotriene modifiers
Zileuton, a 5-lipoxygenase inhibitor; MK-571, pranlukast, 
cinalukast, zafirlukast leukotriene receptor antagonists; 
and iralukast, an LTD4/LTE4 antagonist have produced 
both subjective and objective improvements in asthma Journal of Asthma and Allergy 2009:2 100
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patients.19,23,48,75 Coreno and colleagues compared salmeterol, 
montelukast, zafirlukast, zileuton, and placebo in 10 patients 
using a cycle ergometer and breathing frigid air and found 
that all of the leukotriene-modifying drugs inhibited EIA 
however zileuton was less potent and shorter acting.76
Montelukast in aspirin-sensitive patients
Aspirin sensitive asthmatics are characterized by cysteinyl 
leukotriene overproduction and excrete high amounts in 
their urine.77 They have overexpression of LTC4 synthase on 
bronchial biopsy and a variant of allele C is more common in 
severely effected aspirin-sensitive patients.77 Mastalerz and 
others studied 19 aspirin-sensitive asthmatics by exercise 
challenge and found that a single dose of montelukast 
attenuated or prevented EIB in the majority compared to 
placebo.77
Montelukast limitations/concerns/
safety/tolerability
Not all patients taking montelukast are protected from EIA,3 
with protection ranges typically from 50%–80%.48 As noted 
previously in the Singulair overview section, no biologic 
markers clearly identify antileukotriene medication responders 
from nonresponders.3 The 4 mg and 5 mg preparations contain 
phenylalanine and patients with phenylketonuria should avoid 
them.62 Treatment of airway inflammation with ICS has been 
shown to improve oxygenation and exercise performance due 
to increased alveolar ventilation and improved pulmonary gas 
exchange efficiency.78 Similar studies with montelukast are 
not found in the literature.
Side effects
Most studies suggest leukotrienes receptor antagonists 
are well tolerated11 and montelukast is rated pregnancy 
category B by the US FDA.60,62 It is unknown if montelukast 
is excreted in human milk.62 No evidence of dose-limiting 
toxicity has been noted.59 Montelukast was not associated 
with growth rate reduction as has been seen in inhaled 
corticosteroids.11 No clinically important drug interactions 
with montelukast have been identified.59,60,62 However 
zileuton may affect other drugs’ metabolism and also has 
been associated with liver dysfunction.60 Churg–Strauss 
syndrome has been associated with zafirlukast, but not 
montelukast.11 Physicians are recommended to remain alert 
for eosinophilia, vasculitic rash, and other symptoms.62 
Montelukast has a wide safety margin with no dosage 
adjustment for renal insufficiency or for mild to moderate 
hepatic insufficiency.59 Liver dysfunction has also been 
associated with zafirlukast so monitoring liver function 
has been recommended.60 Post-marketing experiences 
have further documented potential side effects including 
a relatively recent report of an adolescent patient suicide 
while treated with montelukast.40,62
Clinical usage based on patient-
focused perspectives  
and clinical data
Approximately one third of all maintenance therapy 
prescriptions for asthma are for leukotriene inhibitors 
thought to be related to ease of use and dosing, lack of side 
effects, and efficacy60 (Table 2). Montelukast can be used 
intermittently since effectiveness is noted after a single 
dose.3 However, it may be best suited as a daily controller 
for patients with poor inhaler technique or poor compliance, 
patients concerned with inhaled steroid effects, or patients 
with EIB, especially if they continue to have inadequate 
protection from short-acting β2-agonists.16,60 Some clinicians 
use montelukast particularly for children with activity levels 
that are frequent, but at irregular intervals3,7 throughout the 
day, which makes it hard to anticipate pre-exercise β2-agonists 
and perhaps leading to regular and too frequent usage.61 
Given that regular β2-agonists adversely affects EIB, some 
clinicians suggest that they be “prescribed with care particu-
larly in patients with prominent exercise symptoms.”72 As a 
guideline, some authors have suggested that those with EIA 
more than once or twice a week might benefit with use of an 
anti-inflammatory treatment.20
Inhaled corticosteroids have been shown to be more effective 
than montelukast in several measures of asthma control,16 
but this may be different in regards to EIB. Increasing from 
a low dose of an inhaled corticosteroid for uncontrolled 
asthma results in marginal improvement in efficacy and 
may lead to unwanted side effects. Adding a long-acting 
β2-agonist or leukotriene receptor antagonist to improve 
control is recommended.69 In EIA patients, montelukast may 
be advantageous to long-acting β2-agonist add-on therapy.69 
Table 2 Montelukast advantages
Large treatable age range and multiple dosing forms
Once a day
Taken by mouth, easy to swallow or a tasty chewable
improves eiB in the majority of patients
Lack of tolerance
Good safety profile
Abbreviation: eiB, exercise-induced bronchospasm.Journal of Asthma and Allergy 2009:2 101
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The ease of a daily oral tablet at bedtime encourages 
adherence compared to other asthma medications.10,16,20 
In addition, the choice to use long-acting β2-agonist as 
add on treatment for asthma control may adversely affect 
EIA.69 Lastly the lack of tolerance may make montelukast 
preferential to others.3 Neither montelukast nor salme-
terol provided complete bronchoprotection and therefore 
prophylactic use of a short-acting β2-agonist may be neces-
sary15 and should be available for breakthrough symptoms. 
Finding the individually correct therapeutic balance of 
efficacy, tolerability, adherence, and ease of use is left to the 
clinician and caregiver to achieve.16
Conclusions
EIA is an important clinical disease for patients young and old. 
The pathogenesis of EIA remains uncertain, but the biology 
is becoming more clearly understood. Patient symptoms lead 
the clinician to provide confirmatory testing and treatment. 
Many treatment options are available and extrapolating 
study data to an individual patient is complicated. Clinically, 
montelukast is a helpful medication for many patients with 
EIB and is typically well tolerated.
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